Palbociclib and Exemestane are Active in Pretreated Low-Grade Serous Ovarian Cancer

Palbociclib and Exemestane are Active in Pretreated Low-Grade Serous Ovarian Cancer

Review Data

Q: Is the topic relevant to the journal area of interest? Is it contemporary and interesting for

researchers?

A: Good

 

Comments: In the title, “Palbociclib and Exemestane is” must be replaced with “Palbociclib and Exemestane are”.

 

Abstract & Keywords

Q: Are all required components included in the abstract? Are the keywords appropriately chosen?

A: Good

 

Goal

Q: Is the goal explicitly stated in the Introduction? Is its formulation clear and unambiguous?

A: Good

 

Structure

Q: Is the paper's structure coherent? Is it in coherence with the goal of the paper?

A: Good

 

Tools and Methods

Q: Are methods the author uses adequate and well used?

A: Good

 

Discussion & Conclusion

Q: Is it related to the results presented before? Do you consider them as coherent?

A: Good

 

Comments: The Discussion describes the possible therapy for reducing the prognosis of the disease providing relevant literature. This further states that the cell cycle inhibitors, combined with endocrine therapy, are attractive candidates for the treatment of low-grade ovarian cancers in the advanced disease stages. This also highlights that in the early stages of the disease, c-MYC might not be mutated, leading to the characteristic slow progression of low-grade ovarian cancers. Lastly, this report calls for further research in this field.

 

Literature

Q: Does the author utilize relevant literature?

A: Good

 

Author's knowledge

Q: What is the level of the author’s knowledge? Does the author utilize all recent contributions relevant to the topic?

A: Good

 

Length

Q: Is the length of the paper adequate to the significance of the topic? Do you suggest shortening the paper without losing its value?

A: Good

 

Figures & Tables

Q: Does the author use them suitably? Are legend and notations clear?

A: Good

 

Writing style

Q: Is it clear and understandable?

A: Good

 

Comments: There are few issues found in the manuscript which are as follows:

·       In Case Report, 9th sentence, “CA-125 first increased (2440 kU/l) but dropped eventually with resulting in biochemical” must be replaced with “CA-125 first increased (2440 kU/l) but dropped eventually resulting in biochemical”. In 12th sentence, “the patient then seeked advice in our hospital” must be written as “the patient then sought advice in our hospital”.

·       In 24th sentence of Case Report, “of our best knowledge” must be “to our best knowledge,”. And in 25th sentence, “overview low-grade Ovarian Cancer Ovarian Cancer is known as the 4th most lethal cancer type in women” must be “low-grade ovarian cancer is known as the 4th most lethal cancer type in women”.

·       In Discussion, 1st sentence, “we observed a prolonged tumor-control with decreasing tumor-marker and without the need of a further therapy after conducted surgery in the beginning of the disease” must be written as “we observed a prolonged tumor-control with decreasing tumor-marker and without the need for further therapy after conducted surgery in the beginning of the disease”.

 

Further comments on the paper

Comments: This case presents a 55-year-old woman with heavily pretreated rare metastatic micropapillary low grade serous ovarian cancer. Later, KRAS-mutation and c-MYC-amplification was detected. This further highlights a combination therapy with Palbociclib and Exemestane that results in a lasting response, opening a new opportunity for treatment in heavily pretreated metastatic micropapillary low-grade serous ovarian cancer.

 

Q: Would you recommend this manuscript for further publication?

A: Yes - Suitable to be published

If you have any questions and clarifications you can write to the journal.

Thanks,
Science Repository Team

 
 

Author Info

Corresponding Author
Beat Thürlimann
Kantonsspital St. Gallen, St. Gallen, Switzerland

Article Info

Article Type
Case Report
Publication history
Received: Tue 08, Dec 2020
Accepted: Tue 22, Dec 2020
Published: Thu 31, Dec 2020
Copyright
© 2023 Beat Thürlimann. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.CROGR.2020.03.04